Three Questions to Ask When Determining Your Pharma Brand Name Strategy

December 08, 2016

By understanding the general buckets of naming strategies and the scenarios in which these types of names thrive, pharmaceutical companies can hone their naming strategy. At the same time, these teams can hedge their risk by including options from different strategies, specifically blank canvas, to avoid the need to start over. When looking into a naming strategy for your product here are a few questions to consider.

Continue Reading

Risk vs. Reward in Pharmaceutical Brand Naming

November 17, 2016

When developing a pharmaceutical brand name, there are two main paths you can take – either choose a name that is “safe” and has a good chance at regulatory approval, or to take the more “risky” route, with a name that might have a more difficult time getting approved but is sure to stand out in the marketplace. So, which one is best for your brand naming strategy?

Continue Reading

WEBINAR: New Health Canada Regulatory Guidelines: Are You Prepared?

July 17, 2015

In June 2015, Health Canada’s new guidance for the review and submission of drug brand names went into effect bringing with it significant changes in how your drug brand names will be reviewed, and the responsibilities of the drug manufacturers in this new process. To learn more about these changes and how this will impact […]

Continue Reading

Real-Time Marketing: Making It Work For Pharma Branders

May 22, 2014

Real-Time Marketing: Making It Work For Pharma Branders Let’s start by creating a baseline for this topic. What is real-time marketing (RTM)? Of all the attempts to define this marketing strategy, a blog post from Evergage sums it up quite nicely: RTM is “…the practice of brands engaging their audience via content, advertising, and product […]

Continue Reading

Branding Pharmaceutical Drugs in China

June 04, 2013

Did you know according to the Chinese Association for Pharmaceutical Equipment group that the Chinese pharmaceutical industry has been growing at an average annual rate of 16.72% over the last few decades? And that growth isn’t going to slow down anytime soon. China stands at the cusp of a modern society with an increasingly affluent […]

Continue Reading

Why INN’s are so Important to a Drug’s Life

July 01, 2011

Every pharmaceutical asset begins with a nonproprietary, generic name, or an International Nonproprietary Name (INN). This name could potentially be the first strategic decision you make for the commercial life of your brand. But what exactly is an INN name and why do they exist? Since the inception of the INN naming system in 1950 […]

Continue Reading

FDA Approval: Edarbi

February 28, 2011

FDA approves Edarbi to treat high blood pressure (source: FDA Press Announcement) On Friday, February 25, 2011, The U.S. Food and Drug Administration approved Edarbi tablets (azilsartan medoxomil) to treat high blood pressure (hypertension) in adults. Data from clinical studies showed Edarbi to be more effective in lowering 24-hour blood pressure compared with two other […]

Continue Reading